CRIS Current Research Information System

BACCARANI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.373
AS - Asia 23.916
EU - Europa 20.885
AF - Africa 1.500
SA - Sud America 1.448
Continente sconosciuto - Info sul continente non disponibili 1.346
OC - Oceania 34
Totale 81.502
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.914
VN - Vietnam 6.384
CN - Cina 6.290
SG - Singapore 6.262
GB - Regno Unito 5.918
SE - Svezia 3.100
IT - Italia 2.566
DE - Germania 2.548
HK - Hong Kong 1.475
FR - Francia 1.383
IN - India 1.212
RU - Federazione Russa 1.124
UA - Ucraina 1.048
BR - Brasile 1.028
IE - Irlanda 731
NL - Olanda 622
JP - Giappone 536
ZA - Sudafrica 473
EE - Estonia 390
TG - Togo 370
FI - Finlandia 316
KR - Corea 302
CH - Svizzera 272
CA - Canada 270
BD - Bangladesh 260
CI - Costa d'Avorio 218
JO - Giordania 209
AR - Argentina 182
BG - Bulgaria 174
SC - Seychelles 146
NG - Nigeria 129
BE - Belgio 127
PH - Filippine 125
TR - Turchia 121
IR - Iran 100
PL - Polonia 98
GR - Grecia 96
TH - Thailandia 88
AT - Austria 84
ID - Indonesia 84
HR - Croazia 77
IQ - Iraq 76
MX - Messico 75
EC - Ecuador 74
EU - Europa 66
TW - Taiwan 66
ES - Italia 59
SA - Arabia Saudita 55
UZ - Uzbekistan 50
CO - Colombia 43
PK - Pakistan 41
LB - Libano 39
MY - Malesia 36
CL - Cile 34
PY - Paraguay 32
RO - Romania 28
AU - Australia 27
CZ - Repubblica Ceca 27
KE - Kenya 25
VE - Venezuela 25
EG - Egitto 23
TN - Tunisia 22
ET - Etiopia 21
MA - Marocco 21
AE - Emirati Arabi Uniti 20
JM - Giamaica 19
LT - Lituania 18
IL - Israele 17
CR - Costa Rica 15
DZ - Algeria 15
HN - Honduras 15
PE - Perù 14
GT - Guatemala 13
AL - Albania 11
NP - Nepal 10
RS - Serbia 10
PT - Portogallo 9
NI - Nicaragua 8
A2 - ???statistics.table.value.countryCode.A2??? 7
BO - Bolivia 7
DO - Repubblica Dominicana 7
OM - Oman 7
QA - Qatar 7
TT - Trinidad e Tobago 7
BA - Bosnia-Erzegovina 6
BS - Bahamas 6
KZ - Kazakistan 6
MD - Moldavia 6
AZ - Azerbaigian 5
BY - Bielorussia 5
DK - Danimarca 5
GE - Georgia 5
HU - Ungheria 5
KG - Kirghizistan 5
LY - Libia 5
NO - Norvegia 5
PS - Palestinian Territory 5
SK - Slovacchia (Repubblica Slovacca) 5
UY - Uruguay 5
MK - Macedonia 4
Totale 80.136
Salva come PNG Salva come JPEG
Città #
Southend 5.262
Singapore 4.195
Fairfield 3.339
Ashburn 3.055
Chandler 2.418
Woodbridge 1.754
Houston 1.592
Seattle 1.568
Wilmington 1.539
San Jose 1.505
Hong Kong 1.393
Dong Ket 1.340
Ho Chi Minh City 1.207
Cambridge 1.206
Ann Arbor 1.200
Princeton 1.071
Beijing 984
Hanoi 972
Santa Clara 919
Dublin 722
Hefei 681
Boardman 667
Jacksonville 639
Council Bluffs 554
Nanjing 540
Lauterbourg 515
Westminster 471
Padova 461
Tokyo 435
New York 415
Los Angeles 407
Lomé 369
Bologna 332
Helsinki 283
Berlin 272
Buffalo 254
Dallas 254
Jinan 252
Seoul 238
Saint Petersburg 237
Shenyang 227
Abidjan 217
Bern 215
Amman 208
Milan 205
Turin 202
San Diego 201
Changsha 177
Sofia 171
Bremen 166
Hebei 165
Nanchang 161
Haiphong 158
São Paulo 157
Frankfurt am Main 152
Da Nang 145
Chicago 142
Medford 133
Redondo Beach 130
Guangzhou 127
Brussels 117
Jiaxing 117
Tianjin 117
Munich 113
Mülheim 111
Zhengzhou 111
Redmond 107
Florence 106
Abeokuta 105
Shanghai 105
Redwood City 97
Phoenix 88
Falls Church 87
London 84
Orem 84
Rome 84
Hangzhou 83
Norwalk 82
Toronto 82
Haikou 76
Mahé 72
The Dalles 72
Des Moines 70
Can Tho 65
Dearborn 64
Ningbo 60
Warsaw 60
Falkenstein 59
Taiyuan 59
Taizhou 59
Biên Hòa 57
San Francisco 57
Bengaluru 56
Hải Dương 55
Brooklyn 53
Montreal 53
Istanbul 52
Wuhan 52
Verona 51
Yubileyny 51
Totale 52.109
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 391
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 358
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 347
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 347
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia 335
18F-FDG PET early after radiotherapy in lymphoma patients. 321
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 318
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 317
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 314
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 308
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 306
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 295
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 287
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 284
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 281
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 279
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 273
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 270
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 267
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 263
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 259
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 259
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 258
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 258
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 257
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 257
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 257
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 256
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 249
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 248
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 245
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 243
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 241
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 239
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 238
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 236
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 234
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 234
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 233
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 232
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 232
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 231
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 231
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 230
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 228
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 228
Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors. 227
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 227
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 226
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 225
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 224
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 222
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 222
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 222
Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. 221
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 221
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 221
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 220
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 220
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 220
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 220
Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission. 219
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 219
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 218
Advances in the treatment for haematological malignancies. 217
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 217
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia 216
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 215
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 214
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. 214
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 214
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 214
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 213
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 212
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 211
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 211
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 211
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 210
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 210
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 210
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 209
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 208
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 208
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. 208
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 207
Developing a new grading system of ocular surface disease after allogeneic hematopoietic stem cell transplantation (HSCT). 206
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 206
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 205
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 205
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 204
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 204
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 203
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 203
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 202
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 202
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 202
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 202
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 201
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 201
Totale 23.970
Salva come PNG Salva come JPEG
Categoria #
all - tutte 222.353
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 222.353
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228.613 0 265 730 963 912 621 191 619 358 759 1.635 1.560
2022/202310.221 1.237 1.564 582 1.336 672 815 369 531 1.613 235 808 459
2023/20242.521 151 421 151 247 208 599 152 134 87 153 97 121
2024/20259.151 274 1.604 768 685 1.457 482 759 192 66 810 236 1.818
2025/202621.057 1.389 2.172 2.129 1.382 2.530 1.391 1.833 984 4.197 1.717 703 630
2026/20271.435 504 931 0 0 0 0 0 0 0 0 0 0
Totale 81.502